دورية أكاديمية
أعرض في EDS

Active immunization combined with cisplatin confers enhanced therapeutic protection and prevents relapses of HPV-induced tumors at different anatomical sites.

التفاصيل البيبلوغرافية
العنوان: Active immunization combined with cisplatin confers enhanced therapeutic protection and prevents relapses of HPV-induced tumors at different anatomical sites.
المؤلفون: Porchia BFMM; Vaccine Development Laboratory, Department of Microbiology, Biomedical Sciences Institute, University of Sao Paulo, Sao Paulo, SP, Brazil.; ImunoTera Soluções Terapêuticas Ltda., Aps LRMM; Vaccine Development Laboratory, Department of Microbiology, Biomedical Sciences Institute, University of Sao Paulo, Sao Paulo, SP, Brazil.; ImunoTera Soluções Terapêuticas Ltda., Moreno ACR; Vaccine Development Laboratory, Department of Microbiology, Biomedical Sciences Institute, University of Sao Paulo, Sao Paulo, SP, Brazil., da Silva JR; Vaccine Development Laboratory, Department of Microbiology, Biomedical Sciences Institute, University of Sao Paulo, Sao Paulo, SP, Brazil., Silva MO; Vaccine Development Laboratory, Department of Microbiology, Biomedical Sciences Institute, University of Sao Paulo, Sao Paulo, SP, Brazil., Sales NS; Vaccine Development Laboratory, Department of Microbiology, Biomedical Sciences Institute, University of Sao Paulo, Sao Paulo, SP, Brazil., Alves RPDS; Vaccine Development Laboratory, Department of Microbiology, Biomedical Sciences Institute, University of Sao Paulo, Sao Paulo, SP, Brazil., Rocha CRR; DNA Repair Laboratory, Department of Microbiology, Institute of Biomedical Sciences, University of Sao Paulo, Sao Paulo, Brazil., Silva MM; DNA Repair Laboratory, Department of Microbiology, Institute of Biomedical Sciences, University of Sao Paulo, Sao Paulo, Brazil., Rodrigues KB; Vaccine Development Laboratory, Department of Microbiology, Biomedical Sciences Institute, University of Sao Paulo, Sao Paulo, SP, Brazil., Barros TB; Vaccine Development Laboratory, Department of Microbiology, Biomedical Sciences Institute, University of Sao Paulo, Sao Paulo, SP, Brazil., Pagni RL; Vaccine Development Laboratory, Department of Microbiology, Biomedical Sciences Institute, University of Sao Paulo, Sao Paulo, SP, Brazil., Souza PDC; Vaccine Development Laboratory, Department of Microbiology, Biomedical Sciences Institute, University of Sao Paulo, Sao Paulo, SP, Brazil., Diniz MO; Vaccine Development Laboratory, Department of Microbiology, Biomedical Sciences Institute, University of Sao Paulo, Sao Paulo, SP, Brazil.; ImunoTera Soluções Terapêuticas Ltda., Ferreira LCS; Vaccine Development Laboratory, Department of Microbiology, Biomedical Sciences Institute, University of Sao Paulo, Sao Paulo, SP, Brazil.
المصدر: International journal of biological sciences [Int J Biol Sci] 2022 Jan 01; Vol. 18 (1), pp. 15-29. Date of Electronic Publication: 2022 Jan 01 (Print Publication: 2022).
نوع المنشور: Journal Article; Research Support, Non-U.S. Gov't
اللغة: English
بيانات الدورية: Publisher: Ivyspring International Country of Publication: Australia NLM ID: 101235568 Publication Model: eCollection Cited Medium: Internet ISSN: 1449-2288 (Electronic) Linking ISSN: 14492288 NLM ISO Abbreviation: Int J Biol Sci Subsets: MEDLINE
أسماء مطبوعة: Original Publication: Lake Haven, N.S.W., Australia : Ivyspring International, c2004-
مواضيع طبية MeSH: Cancer Vaccines/*pharmacology , Cisplatin/*pharmacology , Neoplasms/*drug therapy , Neoplasms/*virology , Papillomavirus Infections/*complications, Animals ; Mice ; Mice, Inbred C57BL ; Neoplasm Recurrence, Local/prevention & control ; Neoplasms/immunology ; Xenograft Model Antitumor Assays
مستخلص: The active immunotherapy concept relies on the use of vaccines that are capable of inducing antitumor immunity, reversion of the suppressive immunological environment, and long-term memory responses. Previously, antitumor vaccines based on a recombinant plasmid (pgDE7h) or a purified protein (gDE7) led to regression of early-established human papillomavirus (HPV)-associated tumors in a preclinical model. In this work, the anticancer vaccines were combined with cisplatin to treat HPV-induced tumors at advanced growth stages. The antitumor effects were evaluated in terms of tumor regression, induction of specific CD8 + T cells, and immune modulation of the tumor microenvironment. Acute toxicity induced by the treatment was measured by weight loss and histological alterations in the liver and kidneys. Our results revealed that the combination of cisplatin with either one of the tested immunotherapies (pgDE7h or gDE7) led to complete tumor regression in mice. Also, the combined treatment resulted in synergistic effects, particularly among mice immunized with gDE7, including activation of systemic and tumor-infiltrating E7-specific CD8 + T cells, tumor infiltration of macrophages and dendritic cells, and prevention of tumor relapses at different anatomical sites. Furthermore, the protocol allowed the reduction of cisplatin dosage and its intrinsic toxic effects, without reducing antitumor outcomes. These results expand our knowledge of active immunotherapy protocols and open perspectives for alternative treatments of HPV-associated tumors.
Competing Interests: Competing Interests: LRMM. Aps, BFMM Porchia, and MO Diniz hold ownership interest (including patents) in ImunoTera Soluções Terapêuticas Ltda. No potential conflicts of interest were disclosed by the other authors.
(© The author(s).)
References: Cochrane Database Syst Rev. 2016 Nov 22;11:CD005342. (PMID: 27873308)
Anticancer Agents Med Chem. 2007 Jan;7(1):3-18. (PMID: 17266502)
Cancer. 2016 Feb 15;122(4):502-14. (PMID: 26670695)
Lancet. 2017 Oct 7;390(10103):1654-1663. (PMID: 28756902)
Vaccine. 2017 Dec 19;35(52):7240-7249. (PMID: 29174677)
Nat Rev Immunol. 2017 Feb;17(2):97-111. (PMID: 27748397)
Gynecol Oncol. 2017 Jun;145(3):462-468. (PMID: 28233576)
Cancer. 2008 Nov 15;113(10 Suppl):2919-25. (PMID: 18980275)
Sci Transl Med. 2016 Apr 13;8(334):334ra52. (PMID: 27075626)
Eur J Immunol. 1993 Sep;23(9):2242-9. (PMID: 7690326)
Hum Gene Ther. 2013 Oct;24(10):861-70. (PMID: 24007495)
Sci Transl Med. 2012 Oct 10;4(155):155ra138. (PMID: 23052295)
Hum Vaccin Immunother. 2013 Mar;9(3):534-43. (PMID: 23296123)
Curr Opin Virol. 2019 Dec;39:33-40. (PMID: 31465959)
Cancer Immunol Immunother. 2013 Jul;62(7):1175-85. (PMID: 23615841)
Clin Cancer Res. 2008 May 15;14(10):3185-92. (PMID: 18483387)
Lancet Oncol. 2010 Feb;11(2):165-73. (PMID: 20005175)
Antibodies (Basel). 2019 Oct 21;8(4):. (PMID: 31640266)
Mol Pharm. 2011 Dec 5;8(6):2320-30. (PMID: 21985578)
Lancet. 2020 Feb 22;395(10224):575-590. (PMID: 32007141)
Mol Cancer Ther. 2016 Aug;15(8):1920-30. (PMID: 27222537)
Radiother Oncol. 2014 Jun;111(3):374-81. (PMID: 24833558)
BMC Complement Altern Med. 2015 Aug 18;15:283. (PMID: 26283082)
PLoS One. 2015 Jan 05;10(1):e116389. (PMID: 25560237)
Toxicology. 2005 Sep 1;212(2-3):116-23. (PMID: 15946783)
JAMA Netw Open. 2018 Sep 7;1(5):e181999. (PMID: 30646145)
Sci Transl Med. 2013 Feb 13;5(172):172ra20. (PMID: 23408053)
Cancer Res. 2013 Apr 15;73(8):2493-504. (PMID: 23418322)
Gene Ther. 2015 Jul;22(7):528-35. (PMID: 25786869)
Mol Cancer Ther. 2017 Sep;16(9):1922-1933. (PMID: 28522585)
Front Immunol. 2015 Apr 24;6:187. (PMID: 25964783)
J Clin Oncol. 2019 Jun 10;37(17):1470-1478. (PMID: 30943124)
Hum Gene Ther. 2007 Jul;18(7):575-88. (PMID: 17576157)
J Natl Cancer Inst. 2007 Nov 7;99(21):1634-43. (PMID: 17971527)
Cancer Res. 2016 Oct 15;76(20):6017-6029. (PMID: 27569212)
Lancet Glob Health. 2020 Feb;8(2):e191-e203. (PMID: 31812369)
J Transl Med. 2013 Apr 04;11:88. (PMID: 23557172)
Clin Cancer Res. 2014 Nov 1;20(21):5456-67. (PMID: 24893628)
Nat Commun. 2014 Oct 30;5:5317. (PMID: 25354725)
Int J Cancer. 2014 Feb 1;134(3):497-507. (PMID: 23568556)
CA Cancer J Clin. 2018 Nov;68(6):394-424. (PMID: 30207593)
Lancet. 2015 Nov 21;386(10008):2078-2088. (PMID: 26386540)
Cochrane Database Syst Rev. 2012 Jun 13;(6):CD005342. (PMID: 22696349)
Cancer Res. 1996 Jan 1;56(1):21-6. (PMID: 8548765)
فهرسة مساهمة: Keywords: Cancer; HPV; gDE7; immunotherapy; vaccine
المشرفين على المادة: 0 (Cancer Vaccines)
Q20Q21Q62J (Cisplatin)
تواريخ الأحداث: Date Created: 20220103 Date Completed: 20220328 Latest Revision: 20220328
رمز التحديث: 20240628
مُعرف محوري في PubMed: PMC8692155
DOI: 10.7150/ijbs.56644
PMID: 34975315
قاعدة البيانات: MEDLINE
الوصف
تدمد:1449-2288
DOI:10.7150/ijbs.56644